• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees’ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Clara Elinor Grünewald
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

Competition battle for rheumatism drug Hurima – licenses win

26. October 2018

Few days ago, the US pharmaceutical company Abbvie expired the patent protection for its most successful blockbuster drug Hurima in Europe. However, the competition between generic drug manufacturers for the underlying patents began much earlier – in a pioneering way before a UK court.

Landmark decision of the UK court

HurimaIn March 2016, the South Korean drug developer Samsung Bioepis (SB) erzielen, a joint venture between the Korean conglomerate Samsung and US biotech Biogen, filed a declaratory action in the United Kingdom. Samsung Bioepis sought a declaratory judgment that AbbVie’s patents relating to treatment with Hurima were invalid due to lack of inventive novelty. AbbVie was to be prevented from preventing the market launch in Great Britain of a biosimilar version of Hurima from the Korean conglomerate. The treatment of rheumatoid arthritis requires subcutaneous administration of 40 mg Adalimumab (sold under the trade name Hurima) every two weeks.

In a landmark ruling in March 2017, the England and Wales High Court Chancery Division of the Patent Court ruled that the dosage patents (EP 1,406,656 (Patent ‘656) and EP 1,944,322 (Patent ‘322)) were indeed invalid due to lack of inventive step.

In its judgment, the court remarkably emphasized the international significance of the judgment. It also justified its decision with the conduct of patent proprietor AbbVie, in which the court recognized the intention to terminate the proceedings at the last moment and to protect the patent portfolio from examination. The background for this assessment is Abbvie’s approach of maintaining the scope of protection of patent 656 by means of a so-called fourth divisional application, which essentially claimed the same subject-matter as patent 656, but at the same time Abbvie actively abandoned patent 656 in November 2015 – only a few weeks before the start of the proceedings before the UK court. In this way, it was avoided that the British court and the opposition division would have to determine patentability.

The court found this to be an extension of commercial uncertainty to delay the launch of competing Humira biosimilar products. Abbvie denied a connection between the abandonment of the patent and the commencing proceedings. The US pharmaceutical company claimed that a late objection to a remedy led to its decision.

Hurima is considered the most commercially successful drug in the world

Hurima is a particularly attractive product for a variety of generic manufacturers. Three Hurima biosimilars were launched immediately after patent expiry: Hyrimoz by Sandoz (Novartis), Amgevita by Amgen and Imraldi by Biogen. Hulio from Mylan and Fujifilm’s will soon follow, as this has also already received approval in the EU. The same applies to the biosimilar Cyltezo from Boehringer Ingelheim. According to German Handelsblatt, however, the German pharmaceutical company has decided not to launch Cyltezo on the European market due to patent disputes with Abbvie in the USA. In the USA, Amgen had already received approval from the Food and Drug Administration for its Hurima biosimilar Amjevita in 2016. But Amgen was also reluctant to launch the product quickly in order to avoid a possible legal dispute with Abbvie. Because Hurima is a star in the pharmaceutical business. The drug is effective against common diseases such as rheumatism and various other inflammatory immune diseases such as Crohn’s disease and psoriasis. It is the most commercially successful drug in the world.

License agreements for Europe with AbbVie

Accordingly, Abbvie is vigorously fighting worldwide for its patent rights, even after the British judgement. In April 2018, Biogen and Samsung Bioepis announced that they had signed a license agreement for Europe with AbbVie. Under the terms of the agreement, AbbVie will license patents for the use and sale of Imraldi in Europe at the country level, with Biogen and Samsung Bioepis paying royalties, Zenopa News reported. AbbVie, for its part, announced an agreement with Samsung Bioepis and Biogen, which would fend off the biosimilar Imraldi in the US as a competitor to Hurima until 2023, UK Reuters announced in April 2018. This shows once again that licensing agreements can be a silver bullet to avoid lengthy and costly litigation – in the interests of both parties.

Sources:

England and Wales High Court (Patents Court) Decisions of Bailii.org

Picture:

geralt / pixabay.com / CCO License

 

  • share  
  • share 
  • share 
  • tweet  
  • share 

Category iconHealthcare & Lifesciences,  International Intellectual Property,  Patent Law Tag iconPatent,  UK,  Europe,  patent protection,  Hyrimoz by Sandoz,  Amgevita by Amgen,  Imraldi by Biogen,  generic drug manufacturers,  England and Wales High Court Chancery Division of the Patent Court,  UK judgment,  landmark ruling,  License agreements,  successful drug,  AbbVie,  Samsung Bioepis,  Hurima,  patent expiry

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law
This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Recent Posts

  • Action against a patent already expired 26. February 2021
  • Design protection in China: Amendment 2021 25. February 2021
  • EPO practice of national patent offices – more uniform 18. February 2021
  • BGH: Black Forest ham – not only packaged in the Black Forest 16. February 2021

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

26. February 2021
Action against a patent already expired

Action against a patent already expired

18. February 2021
EPO practice of national patent offices – more uniform

EPO practice of national patent offices – more uniform

15. February 2021
Employee’s invention in insolvency

Employee’s invention in insolvency

12. February 2021
Equivalence ruling of BGH: ‘Equivalent means’ in case Crane arm

Equivalence ruling of BGH: ‘Equivalent means’ in case Crane arm

5. February 2021
Trade secret: what are ‘appropriate’ secrecy measures?

Trade secret: what are ‘appropriate’ secrecy measures?

29. January 2021
Brexit: Changes for UK patent attorneys in GER

Brexit: Changes for UK patent attorneys in GER

Footer

Contact

Franklinstr. 61-63
D-60486 Frankfurt am Main
Germany

+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Customer Reviews

Meyer-Dulheuer MD Legal Patentanwälte PartG mbB Patentrecht, Markenrecht, Eigentum hat 4,78 von 5 Sternen 23 Bewertungen auf ProvenExpert.com

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Info secure emails
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • xing
  • Email

Newsletter Signup

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

This form uses Google Recaptcha.

You must accept cookies from Google recaptcha to use this form.

More information can be found in our privacy policy.

load form